Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab + Atezolizumab + Bevacizumab in MSS mCRC
NCT06784947Phase 2Active, not recruiting
- Sponsor
- University of Colorado Denver
- Start
- Mar 2025
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of tiragolumab in colorectal cancer (CRC) (2 arms), sponsored by University of Colorado Denver. Primary endpoint: Objective Response Rate up to 24 months. Started Mar 2025; status: active, not recruiting.
02
Drugs
tiragolumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06784947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06784947.